Eli Lilly Targets Hiked By Analysts Bullish On New Drugs
April 11, 2017 at 14:18 PM EDT
JPMorgan raised its price target on Eli Lilly to $100 from $85, as the firm believes that the company is "well-positioned for sustained growth" given the firm's positive outlook on the company's newer drugs.
